Developmental Research Program

发展研究计划

• 批准号: 10289607
• 负责人: GEROLD BEPLER
• 金额: $ 8.42万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10289607
• 关键词: Advanced Malignant Neoplasm; African American; Area; Award; Cities; Clinical; Collaborations; Communication; Communities; Comprehensive Cancer Center; Development; Disease; Early Diagnosis; Faculty; Fostering; Funding; Future; Goals; Grant; Health; Human Resources; Incidence; Infrastructure; Institutes; Intervention; Laboratories; Malignant Neoplasms; Mentors; Methodology; Methods; Mission; Monitor; Morbidity - disease rate; Patients; Pilot Projects; Population Sciences; Prevention; Process; Program Research Project Grants; Program Reviews; Race; Research; Research Personnel; Research Project Grants; Research Support; Resources; Review Committee; Science; Stage at Diagnosis; Structure; Translating; Translational Research; Underrepresented Minority; United States; Universities; base; cancer health disparity; disparity reduction; health disparity; human subject; innovation; meetings; mortality; novel; programs; recruit; sound; translational impact; treatment response

Project Summary The primary goal of the Developmental Research Program (DRP) of this P20 application is to advance the cancer health disparities research mission at the Karmanos Cancer Institute (KCI) by developing innovative research projects that are scientifically sound and translatable. The DRP provides a unique opportunity for soliciting new research ideas and encourages development of cancer health disparities projects with high translational potential. These projects provide investigators with the resources to conduct high-impact translational research consistent with our P20 SPORE's objectives. The goals will be achieved through the following specific aims: 1) Solicitation of DRP proposals through a highly structured process by leveraging the existing administrative structure of the KCI; 2) Review applications for new and renewal projects by a DRP Review Committee, which will recommend up to two new applications and two renewal applications for funding to the Executive Committee (except for the first year, where two new projects will be supported); 3) Monitor and evaluate funded projects for progress and translational potential, and assess their potential to become full P50 “SPORE-ready” translational projects; and 4) Integrate DRP investigators into the SPORE community by requiring participation in monthly meetings and group communications, and by providing opportunities for expanded collaborations. We will utilize KCI's existing infrastructure for the DRP to meet the translational objectives of the P20 SPORE and leverage already established mechanisms to solicit applications. These mechanisms also serve to foster excellent science in cancer health disparities, recruit new faculty to areas of focus, mentor junior faculty, and encourage research collaborations. PIs of new and renewal DRP projects will be required to submit written summaries of research accomplishments to the DRP Committee after 10 months and present these at one of the monthly meetings of the Executive Committee comprised of the co-leaders of the SPORE projects and core directors. This meeting will be used to determine whether the DRP projects are sufficiently meritorious for consideration as full translational projects by the Internal Advisory Board, followed by the EAB and the P20 Cancer Action Council, as part of a future Detroit Cancer Health Disparities P50 SPORE application. This program will encourage participation from a broad range of investigators at KCI and Wayne State University by providing support for pilot projects with the potential to develop into impactful translational projects. It also encourages and facilitates the development of new research directions, methodologies, and collaborations. Importantly, KCI has committed to provide the required funds annually for the DRP to fund up to two new projects every year at a maximum of $50,000 per project per year (with the potential of renewal for up to two projects per year in years 2 and 3).

项目摘要 该P20应用程序的发展研究计划（DRP）的主要目标是促进癌症 Karmanos癌症研究所（KCI）的健康差异研究使命，通过开发创新研究 科学合理且可翻译的项目。DRP提供了一个独特的机会，征求新的 研究思路，并鼓励发展癌症健康差异项目，具有高转化率 潜力这些项目为研究人员提供了进行高影响力转化研究的资源 符合我们P20 SPORE的目标。这些目标将通过以下具体目标实现：1） 通过高度结构化的流程，利用现有的行政 KCI的结构; 2）由DRP审查委员会审查新项目和更新项目的申请， 我会向执行委员会推荐最多两项新申请及两项续期申请， （第一年除外，第一年将支持两个新项目）; 3）监测和评估资助的项目， 进展和翻译潜力，并评估其成为完整P50“孢子就绪”翻译的潜力 项目;以及4）通过要求参与每月一次的 会议和小组交流，并提供扩大合作的机会。我们将利用 KCI现有的DRP基础设施，以满足P20 SPORE的转换目标，并利用 已经建立了征求申请的机制。这些机制也有助于促进优秀的 癌症健康差异的科学，招募新的教师到重点领域，指导初级教师，并鼓励 研究合作。新的和更新的DRP项目的PI将被要求提交书面摘要， 10个月后向DRP委员会提交研究成果，并在每月的一次会议上提交 执行委员会会议由SPORE项目的共同领导人和核心董事组成。 这次会议将用于确定DRP项目是否值得考虑 作为内部咨询委员会的全面转化项目，随后是EAB和P20癌症行动 理事会，作为未来底特律癌症健康差异P50 SPORE应用的一部分。此程序将 鼓励KCI和韦恩州立大学的广泛研究人员参与， 支持有潜力发展成为有影响力的转化项目的试点项目。委员会还鼓励 并促进新的研究方向，方法和合作的发展。重要的是，KCI 已承诺每年为“发展研究计划”提供所需的拨款，以资助每年最多两个新项目， 每个项目每年最多50，000美元（每年最多可续签两个项目 第2和第3段）。